Jane Chung Sutro Biopharma, Inc. (STRO) insider trading activity

Jane Chung is Chief Executive Officer of SUTRO BIOPHARMA, INC.. Currently has a direct ownership of 13,891 shares of STRO, which is worth approximately $13,196. The most recent transaction as insider was on Dec 12, 2025, when has been sold 894 shares (Common Stock) at a price of $8.02 per share, resulting in proceeds of $7,169. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 13.9K

87.41% 3M change

80.25% 12M change

Total Value Held $13,196

Jane Chung Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 12 2025	SELL Payment of exercise price or tax liability	$7,169 $8.02 p/Share	894 Reduced 6.05%	13,891 Common Stock
Dec 12 2025	BUY Exercise of conversion of derivative security	-	2,500 Added 14.46%	14,785 Common Stock
Oct 15 2025	BUY Open market or private purchase	$10,000 $0.8 p/Share	12,500 Added 9.24%	122,850 Common Stock
Aug 09 2025	SELL Payment of exercise price or tax liability	$5,366 $0.8 p/Share	6,708 Reduced 5.73%	110,350 Common Stock
Aug 09 2025	BUY Exercise of conversion of derivative security	-	18,750 Added 13.81%	117,058 Common Stock
Mar 04 2025	SELL Payment of exercise price or tax liability	$3,314 $1.42 p/Share	2,334 Reduced 2.32%	98,308 Common Stock
Mar 04 2025	BUY Exercise of conversion of derivative security	-	7,875 Added 7.26%	100,642 Common Stock

Mar 01 2025	SELL Payment of exercise price or tax liability	$15,025 $1.59 p/Share	9,450 Reduced 9.25%	92,767 Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	31,875 Added 23.77%	102,217 Common Stock
Dec 01 2024	SELL Payment of exercise price or tax liability	$23,994 $2.69 p/Share	8,920 Reduced 11.25%	70,342 Common Stock
Dec 01 2024	BUY Exercise of conversion of derivative security	-	25,000 Added 23.98%	79,262 Common Stock
Aug 09 2024	SELL Payment of exercise price or tax liability	$20,869 $3.12 p/Share	6,689 Reduced 10.97%	54,262 Common Stock
Aug 09 2024	BUY Exercise of conversion of derivative security	-	18,750 Added 23.53%	60,951 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$10,581 $4.79 p/Share	2,209 Reduced 4.97%	42,201 Common Stock
Mar 04 2024	BUY Exercise of conversion of derivative security	-	7,875 Added 15.06%	44,410 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$10,088 $4.95 p/Share	2,038 Reduced 5.28%	36,535 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	6,875 Added 15.13%	38,573 Common Stock
Aug 09 2023	SELL Payment of exercise price or tax liability	$27,358 $4.22 p/Share	6,483 Reduced 16.98%	31,698 Common Stock
Aug 09 2023	BUY Exercise of conversion of derivative security	-	18,750 Added 32.93%	38,181 Common Stock
Aug 09 2022	SELL Payment of exercise price or tax liability	$42,788 $6.6 p/Share	6,483 Reduced 30.51%	14,767 Common Stock
Aug 09 2022	BUY Exercise of conversion of derivative security	-	18,750 Added 46.88%	21,250 Common Stock

Also insider at

VIRX

Viracta Therapeutics, Inc. Healthcare

Jane Chung

Chief Executive Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells STRO shares.

Notify only if

Value

Insider Trading

Get notified when an Sutro Biopharma, Inc. insider buys or sells STRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUTRO BIOPHARMA, INC.

Track Activities on STRO

Account